asthma: A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors resulting in recurring periods of wheezing (a whistling sound while breathing), chest tightness, shortness of breath, mucus production and coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
188 |
4. Check minimum number of eventsNone |
188 |
5. Include endpointsNone |
188 |
6. Filter based on genotype QC (FinnGen only) |
188 |
Control definitions (FinnGen only)
- Control exclude
- IBD_BACT_INTEST_INFECTIONS
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- A04
- Name in latin
- Enteritis a Yersinia enterocolitica
Similar endpoints
↥List of similar endpoints to
Enteritis due to Yersinia enterocolitica
based on the number of shared cases.
Similar with more cases:
- Bacterial intestinal infections, IBD co-morbidities
- Infections, IBD-co-morbidities
- Intestinal infectious diseases
- Certain infectious and parasitic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1504 | 800 | 693 |
| Only index persons | 1361 | 727 | 634 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 40.57 | 43.10 | 37.23 |
| Only index persons | 39.86 | 42.41 | 36.93 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 188 | 106 | 82 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 45.73 | 42.82 | 49.50 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 163
- Matched controls
- 1628
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A04.6
ICD-10 Finland
Enteritis due to Yersinia enterocolitica
3853.9
141.8
116
*
M03.2*A04.6
ICD-10 Finland
Postinfectious arthropathy in enteritis due to Yersinia enterocolitica
+∞
56.6
51
*
J01MA02
ATC
ciprofloxacin; systemic
4.7
18.9
95
375
A07EC01
ATC
sulfasalazine; oral, rectal
6.7
14.2
38
71
M13.9
ICD-10 Finland
Arthritis, unspecified
8.0
12.6
29
43
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
5.2
12.6
42
102
H02AB06
ATC
prednisolone; systemic
3.0
10.4
92
489
UJF32
NOMESCO Finland
Coloscopy
3.4
10.1
57
220
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
8.6
9.5
20
26
0084D
ICD-9 Finland
Intestinal infections due to other organisms, Other specified bacteria[ENTERITIS YERSINIA PSEUDOTUBERCULOSA]
+∞
9.5
9
*
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
52.8
8.8
10
*
M03.2
ICD-10 Finland
Other postinfectious arthropathies in diseases classified elsewhere
94.6
8.5
9
*
P01BA02
ATC
hydroxychloroquine; oral
5.0
8.4
27
62
A02BC02
ATC
pantoprazole; systemic
2.6
7.8
113
751
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.6
7.7
74
390
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
10.1
7.4
14
15
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
5.1
7.4
23
51
M02.1
ICD-10 Finland
Postdysenteric arthropathy
31.5
7.2
9
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.0
6.9
44
178
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
7.9
6.6
14
19
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
6.0
6.5
17
31
R50.9
ICD-10 Finland
Fever, unspecified
3.3
6.5
33
116
M45
ICD-10 Finland
Ankylosing spondylitis
7.7
6.0
13
18
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
93
5.53
18.85
2.5
1.4
—
—
—
0
0
23
35
7.35
14.84
1.9
1.6
—
—
—
0
0
23
40
6.41
13.08
1.5
1.2
—
—
—
0
0
150
1092
2.85
7.96
6.7
3.7
15.1
10.1
mm/h
3.03
143
1007
60
323
2.26
5.93
2.7
1.9
3.2
3.1
mg/l
0.11
52
278
121
857
2.16
5.89
13.9
9.7
4.2
4.1
e9/l
0.17
113
763
63
354
2.17
5.56
2.9
3.0
15947.9
3452.4
umol/l
0.56
58
310
17
48
3.79
5.46
1.4
1.4
0.3
0.1
iu/ml
—
5
8
106
729
2.04
5.40
6.4
5.0
0.0
0.0
estimate
0.00
18
136
105
720
2.04
5.39
5.0
3.6
0.0
0.0
estimate
0.00
17
136
95
630
2.03
5.34
3.2
2.6
124.9
99.0
ug/l
0.34
89
589
11
22
5.25
5.33
1.4
1.7
—
—
—
0
0
11
22
5.25
5.33
1.4
1.7
—
—
—
0
0
11
23
5.02
5.08
1.4
1.7
—
—
—
0
0
11
23
5.02
5.08
1.4
1.7
—
—
—
0
0
11
23
5.02
5.08
1.4
1.7
—
—
—
0
0
11
23
5.02
5.08
1.4
1.7
—
—
—
0
0
17
51
3.57
5.02
1.4
1.1
—
—
—
0
0
17
51
3.57
5.02
1.4
1.1
—
—
—
0
0
78
494
1.99
4.89
3.9
3.7
35.5
39.7
ng/l
0.12
51
317
105
737
1.96
4.87
5.0
3.6
0.0
0.0
estimate
0.00
17
128
18
59
3.27
4.65
1.8
1.5
—
—
—
0
0
60
357
2.00
4.41
1.3
1.3
0.8
0.8
u/ml
0.10
21
95
173
1497
2.95
4.22
22.1
11.8
24.4
21.6
mg/l
0.52
143
1159
21
82
2.76
4.05
1.0
1.0
—
—
—
0
0
20
78
2.75
3.86
6.7
2.7
1.6
1.4
mmol/l
0.09
14
58
10
26
4.01
3.57
1.3
1.3
—
—
—
0
0
73
493
1.79
3.52
4.5
2.9
—
—
—
0
0
109
833
1.73
3.35
4.3
4.4
6.3
6.7
mmol/l
0.94
104
752
81
572
1.73
3.30
4.9
3.6
—
—
—
0
0
83
594
1.71
3.20
6.3
5.6
1.2
1.2
mmol/l
0.20
78
548
37
211
1.94
2.99
4.7
2.6
5.2
3.7
e6/l
0.23
28
108
42
251
1.87
2.95
1.1
1.3
2.6
12.9
u/ml
1.85
20
100
88
651
1.66
2.93
9.9
6.6
1.2
1.2
mmol/l
0.30
82
550
48
303
1.78
2.83
1.6
1.5
18.3
21.8
nmol/l
1.27
43
261
58
388
1.72
2.79
4.7
3.6
0.0
0.0
estimate
0.00
18
129
23
113
2.18
2.75
8.7
4.5
5.9
5.7
kpa
0.71
23
113
158
1381
1.90
2.69
18.9
11.0
86.0
86.4
ml/min/173m2
0.07
132
1110
5
7
7.30
2.56
1.4
1.7
—
—
—
0
0
5
7
7.30
2.56
1.4
1.7
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
7
7.30
2.56
1.4
1.3
—
—
—
0
0
5
7
7.30
2.56
1.4
1.7
—
—
—
0
0
5
7
7.30
2.56
1.4
1.7
—
—
—
0
0
37
223
1.82
2.52
4.0
2.5
0.9
0.8
e6/l
0.03
28
119
12
45
2.78
2.50
1.8
2.2
—
—
—
0
0
20
98
2.16
2.42
1.5
1.3
—
—
—
0
0
12
47
2.66
2.32
1.2
1.3
—
—
—
0
0
10
36
2.88
2.24
1.6
1.8
469.3
443.6
mg/l
—
10
36
10
36
2.88
2.24
2.5
2.5
—
—
—
0
0
34
209
1.77
2.17
1.7
1.8
—
—
—
0
0
12
51
2.45
1.99
2.3
2.5
—
—
—
0
0
7
21
3.42
1.98
1.4
1.1
—
—
—
0
0
54
385
1.56
1.96
4.1
2.7
0.1
0.3
e6/l
1.64
44
282
9
33
2.81
1.96
1.4
1.8
—
—
—
0
0
6
16
3.84
1.95
1.3
1.3
—
—
—
0
0
47
328
1.58
1.86
3.8
3.4
641.3
1232.9
ng/l
1.29
42
274
61
452
1.52
1.85
2.6
3.0
2.4
2.4
mmol/l
1.56
55
403
6
18
3.41
1.76
2.0
1.3
—
—
—
0
0
6
18
3.41
1.76
1.5
1.7
—
—
—
0
0
8
30
2.74
1.74
1.4
1.4
—
—
—
0
0
7
24
2.99
1.74
1.4
1.7
—
—
—
0
0
5
13
3.92
1.72
2.2
1.5
—
—
—
0
0
67
513
1.48
1.72
2.1
1.8
92.5
96.8
pmol/l
0.28
36
241
38
257
1.60
1.71
3.7
3.1
85.0
173.7
ng/l
0.41
26
178
6
20
3.06
1.59
1.5
1.7
—
—
—
0
0
21
123
1.80
1.59
1.9
1.8
—
—
—
0
0
7
27
2.65
1.53
1.0
1.4
—
—
—
0
0
37
256
1.55
1.52
1.8
2.3
—
—
—
0
0
6
21
2.92
1.52
1.2
1.5
—
—
—
0
0
6
21
2.92
1.52
1.5
1.7
—
—
—
0
0
31
207
1.60
1.47
1.6
1.7
1027.7
1267.3
nmol/l
0.87
25
165
6
23
2.66
1.38
1.2
1.3
—
—
—
0
0
6
23
2.66
1.38
1.2
1.3
—
—
—
0
0
6
24
2.55
1.31
1.5
1.4
—
—
—
0
0
10
48
2.14
1.30
2.6
2.2
—
—
—
0
0
5
18
2.82
1.29
1.0
1.2
—
—
—
0
0
5
18
2.82
1.29
1.2
1.1
—
—
—
0
0
44
329
1.44
1.25
2.5
2.0
—
—
—
0
0
11
57
1.99
1.19
1.4
1.3
—
—
—
0
0
34
244
1.48
1.19
1.6
2.1
—
—
—
0
0
23
152
1.58
1.15
2.1
1.9
—
—
—
0
0
9
46
2.00
1.05
1.6
2.2
—
—
—
0
0
35
260
1.43
1.03
1.3
1.3
28.1
33.1
iu/ml
0.12
11
83
30
217
1.46
1.02
2.5
2.6
2.4
2.4
mmol/l
0.13
25
193
9
49
1.88
1.00
1.0
1.1
—
—
—
0
0
9
51
1.80
0.96
1.3
1.6
—
—
—
0
0
10
55
1.86
0.94
1.3
2.1
38.6
45.1
u/l
—
10
49
12
73
1.69
0.84
1.6
1.2
—
—
—
0
0
6
32
1.90
0.82
1.0
1.1
—
—
—
0
0
21
148
1.47
0.82
1.8
1.6
—
—
—
0
0
80
698
1.25
0.78
5.0
3.8
—
—
—
0
0
123
1133
1.25
0.72
4.3
3.9
14.7
14.7
pmol/l
0.07
118
1039
5
28
1.81
0.66
1.2
1.8
—
—
—
0
0
18
129
1.44
0.66
2.6
2.2
426.4
398.2
nmol/l
0.24
18
116
120
1108
1.23
0.66
3.5
3.4
—
—
—
0
0
12
79
1.55
0.64
4.3
7.6
24.5
24.2
mmol/l
0.08
12
73
5
29
1.74
0.64
1.8
1.1
—
—
—
0
0
5
29
1.74
0.64
1.2
1.3
—
—
—
0
0
156
1485
1.30
0.63
4.7
4.4
2.8
2.8
mmol/l
0.06
149
1372
154
1465
1.28
0.62
4.1
4.1
4.7
4.7
mmol/l
0.20
146
1365
5
30
1.68
0.62
1.6
1.3
—
—
—
0
0
12
173
0.67
0.61
3.5
4.1
26.3
30.9
%
—
6
115
0
20
0.00
0.60
0.0
1.7
—
7.2
—
0
9
8
52
1.56
0.60
2.6
2.9
23.4
2744.9
u/ml
—
8
46
153
1457
1.27
0.59
4.1
4.0
1.5
1.5
mmol/l
0.06
145
1351
12
81
1.51
0.58
4.8
6.2
25.1
25.2
mmol/l
0.03
12
81
19
143
1.37
0.55
1.8
1.5
—
—
—
0
0
6
38
1.60
0.55
1.5
1.2
—
—
—
0
0
9
61
1.50
0.54
17.4
3.6
48.6
50.9
%
—
9
61
176
1712
1.44
0.53
30.6
17.8
132.7
137.0
g/l
3.61
176
1685
14
101
1.42
0.51
1.9
2.8
70.0
73.4
ml/min/173m2
—
8
41
38
320
1.24
0.50
1.9
1.9
0.9
1.1
mg/l
0.55
32
252
10
69
1.47
0.45
1.6
1.5
—
—
—
0
0
43
372
1.20
0.44
4.8
3.7
24.0
15.3
mg/mmol
0.29
34
229
32
269
1.23
0.43
1.5
1.5
—
—
—
0
0
5
32
1.58
0.42
1.2
1.6
—
—
—
0
0
17
215
0.77
0.42
2.1
1.8
1.2
1.4
%
0.72
17
191
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
8
61
1.33
0.40
11.5
4.0
26.0
24.3
mmol/l
—
8
61
147
1413
1.18
0.39
4.3
4.1
5.7
5.8
mmol/l
1.02
136
1302
0
19
0.00
0.39
0.0
3.7
—
98.9
—
0
19
9
67
1.36
0.38
2.1
3.0
0.9
1.3
%
—
9
67
10
72
1.41
0.37
1.3
2.9
65.3
65.6
u/ml
—
10
72
6
41
1.48
0.36
1.2
1.6
—
—
—
0
0
10
74
1.37
0.33
1.1
1.4
279.0
294.3
miu/ml
—
5
40
43
385
1.15
0.30
2.5
2.0
187.5
367.8
u/l
0.48
43
369
19
159
1.22
0.28
1.6
1.6
—
—
—
0
0
35
311
1.15
0.27
4.3
4.2
25.5
22.9
%
0.43
13
134
5
74
0.67
0.26
1.2
1.5
669.8
307.9
mu/l
—
5
67
10
78
1.30
0.24
4.1
2.1
113.8
132.1
ng/l
—
10
67
5
41
1.23
0.22
1.2
1.7
—
—
—
0
0
15
127
1.20
0.20
3.1
3.2
—
—
—
0
0
6
52
1.16
0.19
1.5
1.7
—
—
—
0
0
18
157
1.16
0.18
7.8
8.0
—
—
—
0
0
110
1069
1.07
0.14
3.8
2.8
44.7
45.6
u/l
0.05
103
1027
144
1413
1.08
0.14
20.1
12.8
38.4
40.5
%
1.81
114
1099
25
229
1.11
0.13
2.5
2.7
0.8
0.7
ug/l
0.19
13
133
16
146
1.10
0.08
3.8
7.9
2.2
1.0
mmol/l
1.43
11
112
5
63
0.79
0.08
1.4
1.5
—
—
—
0
0
7
68
1.03
0.08
1.7
1.5
—
—
—
0
0
7
68
1.03
0.08
1.7
1.5
—
—
—
0
0
7
68
1.03
0.08
1.7
1.5
—
—
—
0
0
8
75
1.07
0.07
1.5
1.8
—
—
—
0
0
36
346
1.05
0.06
1.5
1.6
—
—
—
0
0
11
100
1.11
0.05
5.4
3.6
1.2
1.2
mmol/l
0.60
11
93
139
1381
1.03
0.02
5.3
4.5
1.8
1.9
mu/l
0.75
131
1269
134
1332
1.02
0.01
6.5
5.2
38.9
39.1
mmol/mol
0.08
128
1252
13
124
1.05
0.00
1.6
1.5
—
—
—
0
0
142
1414
1.02
0.00
3.9
3.6
1.3
1.3
mmol/l
0.09
133
1304
15
146
1.03
0.00
3.9
7.7
5.1
5.1
kpa
0.02
15
139
15
146
1.03
0.00
3.9
7.7
11.0
12.2
kpa
0.85
15
140
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
13.5
—
0
6
7
71
0.99
0.00
1.9
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
6
64
0.94
0.00
1.3
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint YERSINIAENTERITIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| YERSINIAENTERITIS | 1.696 [1.28, 2.24] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.191 |
During the follow-up period (1.1.1998 — 31.12.2019), 105 out of 626 females with YERSINIAENTERITIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| YERSINIAENTERITIS | 1.525 [1.11, 2.1] | 0.01 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 71 out of 526 males with YERSINIAENTERITIS died.
Mortality risk
Mortality risk for people of age
years, who have YERSINIAENTERITIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.154% | 0.26% |
| 5 | 1.027% | 1.703% |
| 10 | 2.513% | 4.274% |
| 15 | 4.725% | 8.398% |
| 20 | 8.16% | 14.254% |
Relationships between endpoints
↥Index endpoint: YERSINIAENTERITIS – Enteritis due to Yersinia enterocolitica
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data